VQ Biomedical is developing a minimally invasive catheter that delivers supplemental oxygen directly into the bloodstream, offering an alternative to mechanical ventilation and extracorporeal membrane oxygenation (ECMO) for patients with acute respiratory distress syndrome (ARDS). This approach allows the lungs to rest and recover while reducing risks and complexity associated with traditional respiratory support methods. Founded in 2023 and based in Apex, NC, the company has raised over $5 million in funding—including seed investments and contracts from BARDA and DARPA—to advance its prototype, support preclinical development, and prepare for human trials.
